Search

Amphastar Pharmaceuticals Inc

Fermé

SecteurSoins de santé

23.58 -0.25

Résumé

Variation du prix de l'action

24h

Actuel

Min

23.47

Max

23.8

Chiffres clés

By Trading Economics

Revenu

24M

30M

Ventes

13M

184M

P/E

Moyenne du Secteur

14.148

56.432

BPA

0.8

Marge bénéficiaire

16.502

Employés

1,976

EBITDA

12M

45M

Recommandations

By TipRanks

Recommandations

Neutre

Prévisions sur 12 Mois

-6.15% downside

Dividendes

By Acuity

Prochains Résultats

5 nov. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

171M

1B

Ouverture précédente

23.83

Clôture précédente

23.58

Sentiment de l'Actualité

By Acuity

40%

60%

120 / 339 Classement par Healthcare

Amphastar Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

18 sept. 2026, 23:31 UTC

Amphastar Pharmaceuticals, Inc. is trading lower in after-market hours, continuing a trend of losses with the last three sessions closing lower.

16 sept. 2026, 19:43 UTC

Amphastar Pharmaceuticals, Inc. is advancing, having peaked earlier in the session, and remains above its 20-day moving average near the upper end of its one-month range.

10 sept. 2026, 20:01 UTC

Amphastar Pharmaceuticals shares are higher Thursday, despite earlier session pullbacks. No specific news was identified to explain the price movement.

8 sept. 2026, 20:01 UTC

News

Amphastar Pharmaceuticals is lower today amid a decline in the Pharmaceuticals sub-sector. Analysts recommend "Reduce," with Bank of America reiterating an “underperform” rating.

4 sept. 2026, 20:07 UTC

Amphastar Pharmaceuticals is lower today amid broader market declines following a strong jobs report, which has increased selling pressure across risk assets.

3 sept. 2026, 19:56 UTC

Amphastar Pharmaceuticals is trading roughly flat amid broader market fluctuations. Treasury yields declined following initial jobless claims data that exceeded expectations.

2 sept. 2026, 20:08 UTC

Amphastar Pharmaceuticals is advancing during Wednesday's session, despite earlier pulling back from a session high. No specific news was identified to explain the movement.

26 août 2026, 20:08 UTC

Amphastar Pharmaceuticals is trading higher today, reflecting a broader market trend amid mixed performance following recent inflation data. The stock remains near its one-month range.

25 août 2026, 20:07 UTC

Amphastar Pharmaceuticals is higher during Tuesday's session, reflecting a recovery after three consecutive lower finishes amid easing Treasury yields and falling oil prices.

24 août 2026, 21:01 UTC

Amphastar Pharmaceuticals shares are lower in after-market hours, continuing a five-session decline. No specific news was identified to explain the price movement.

21 août 2026, 19:56 UTC

Amphastar Pharmaceuticals Inc shares are lower today, despite earlier fluctuations. No specific news has been identified to explain the price movement.

20 août 2026, 19:51 UTC

Amphastar Pharmaceuticals shares are higher, supported by a positive market environment and economic indicators showing strength in the broader economy.

19 août 2026, 19:36 UTC

News

Barclays raised its price target on Amphastar Pharmaceuticals to $23.00, contributing to positive sentiment as shares remain well above their 20-day moving average.

18 août 2026, 19:16 UTC

Amphastar Pharmaceuticals Inc shares are higher today, reflecting market volatility amid rising U.S. Treasury yields and inflation concerns linked to geopolitical tensions.

17 août 2026, 19:16 UTC

Amphastar Pharmaceuticals Inc. shares are lower amid routine market fluctuations and concerns over slowing growth following declines in U.S. retail sales and consumer sentiment.

14 août 2026, 20:01 UTC

Amphastar Pharmaceuticals is trading higher, rebounding from an early session low. The stock remains above its 20-day moving average despite no specific news.

12 août 2026, 20:06 UTC

Amphastar Pharmaceuticals Inc shares are lower in Wednesday's session, continuing a decline from Tuesday's close amid fluctuating U.S. Treasury yields and inflation data.

11 août 2026, 19:56 UTC

News

Amphastar Pharmaceuticals reported Q2 revenue of $183.9 million, exceeding expectations. Shares are modestly higher amid strong demand for key products and new launches.

10 août 2026, 19:36 UTC

News

Amphastar Pharmaceuticals reported Q2 earnings of $0.70 per share on $183.9 million in revenue, but shares are trading lower today amid a slight net income decline.

7 août 2026, 19:51 UTC

News

Amphastar Pharmaceuticals reported Q2 EPS of $0.91, exceeding estimates. Revenue also surpassed expectations, contributing to a positive market response and higher shares.

6 août 2026, 23:02 UTC

News

Amphastar Pharmaceuticals reported second-quarter sales of $183.9 million, exceeding expectations. Shares are trading higher in after-market hours following the strong results.

4 août 2026, 19:51 UTC

Amphastar Pharmaceuticals is trading lower today, breaking a trend of higher daily closes. No specific news was identified to explain the decline.

3 août 2026, 19:46 UTC

Amphastar Pharmaceuticals Inc is trading higher, reaching a session high amid positive market conditions and falling oil prices influencing investor sentiment.

31 juil. 2026, 19:36 UTC

Amphastar Pharmaceuticals is declining today, continuing a downward trend since Thursday. The stock reached a session low earlier this morning amid broader market volatility.

30 juil. 2026, 19:28 UTC

Amphastar Pharmaceuticals Inc. shares are lower amid significant downward pressure in the Pharmaceuticals sub-sector, reflecting broader sector weakness during Thursday's session.

29 juil. 2026, 20:41 UTC

Amphastar Pharmaceuticals shares are lower in after-market trading, continuing a decline amid rising crude oil prices and geopolitical tensions in the Middle East.

28 juil. 2026, 20:02 UTC

Amphastar Pharmaceuticals shares are higher today, diverging from a broader market decline amid a sell-off in technology stocks across Asian markets.

24 juil. 2026, 19:06 UTC

Amphastar Pharmaceuticals is trading higher, supported by a pullback in crude oil prices, which has eased some inflationary pressures affecting investor sentiment.

22 juil. 2026, 20:06 UTC

Amphastar Pharmaceuticals Inc shares are lower today, continuing a four-session decline amid market uncertainty ahead of the Federal Reserve meeting on July 29.

21 juil. 2026, 19:46 UTC

Amphastar Pharmaceuticals Inc is trading lower, continuing a three-session decline. No specific news was identified to explain the stock's performance.

Comparaison

Variation de prix

Amphastar Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

-6.15% baisse

Prévisions sur 12 Mois

Moyen 22.167 USD  -6.15%

Haut 30 USD

Bas 20 USD

Basé sur 6 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Neutre

6 ratings

0

Achat

5

Maintien

1

Vente

Sentiment

By Acuity

120 / 339Classement par Soins de santé

Sentiment de l'Actualité

Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Amphastar Pharmaceuticals Inc

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.